FBIOP — Fortress Biotech, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1429260 ·
Last close
$18.88
Market Cap
$1.07B
52W High
$21.43
52W Low
$13.25
ADV30
12,020
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 16,038,000 | 9,820,000 | -7,739,000 | 110,373,000 | 356,874,000 | 255,841,000 | 154,500,000 |
| Dec 2025 | 16,079,000 | 10,639,000 | -4,789,000 | -3,937,000 | 185,548,000 | 79,381,000 | 123,365,000 |
| Sep 2025 | 17,631,000 | 11,876,000 | -6,811,000 | 5,850,000 | 181,407,000 | 86,218,000 | 116,222,000 |
| Jun 2025 | 16,413,000 | 11,474,000 | -36,473,000 | 15,486,000 | 159,895,000 | 74,386,000 | 122,512,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$157,637,000
Investing CF
$8,956,000
Financing CF
$-2,091,000
CapEx
—
Dividends Paid
$-498,000
Buybacks
$-14,450,000
EPS Diluted TTM
—
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-623,679,000
Inventory
$9,292,000
Receivables
$25,508,000
ST Investments
—
EBIT TTM
$141,245,000
Pretax Income TTM
$133,280,000
Interest Exp TTM
$7,965,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$66,161,000
EBITDA
$-50,954,000
Free Cash Flow
$14,971,000
Enterprise Value
$465,131,072
Total Cash
$255,840,992
Total Debt
$53,627,000
Shares Out
56,679,500
Trailing EPS
$-0.86
Book Value
$4.89
ROE
109.8%
ROA
-13.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 63,262,000 | -70,221,000 | 6,815,000 | 185,548,000 | 123,365,000 | — | -65,777,000 |
| Dec 2024 | 57,675,000 | -111,240,000 | -45,997,000 | 144,223,000 | 145,867,000 | — | -80,191,000 |
| Dec 2023 | 84,513,000 | -139,199,000 | -60,637,000 | 167,526,000 | 165,939,000 | — | -128,225,000 |
| Dec 2022 | 75,743,000 | -203,564,000 | -86,575,000 | 294,301,000 | 244,276,000 | — | -179,401,000 |
| Dec 2021 | — | — | — | — | — | — | — |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IVA | Inventiva S.A. | $1.06B | $4.48 | — |
| WVE | Wave Life Sciences Ltd. | $1.09B | $5.51 | — |
| ANRO | Alto Neuroscience, Inc. | $1.05B | $27.07 | — |
| SPTX | Seaport Therapeutics, Inc. | $1.10B | $20.46 | — |
| PCRX | Pacira BioSciences, Inc. | $1.04B | $26.41 | — |
News headlines (Yahoo Finance, 1h cache)
Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing
2026-07-27 12:00 · Yahoo
Journey Medical (DERM) Stock Draws Fresh Price Target Split After Fortress Valuation Changes
2026-06-25 04:29 · Yahoo
Journey Medical Corporation to Participate in A.G.P.’s Annual Virtual Healthcare Conference
2026-05-19 20:45 · Yahoo
Fortress Biotech to Participate in A.G.P.’s Annual Virtual Healthcare Conference
2026-05-18 12:30 · Yahoo
Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
2026-05-14 20:10 · Yahoo
Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
2026-05-13 20:01 · Yahoo
Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026
2026-05-06 20:01 · Yahoo
Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
2026-05-04 12:30 · Yahoo
Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™
2026-04-21 12:30 · Yahoo
Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights
2026-03-31 20:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.